Based upon the frank male bias in HCC incidence and mortality along with abundant pre-clinical support for the role of AR in HCC, AR inhibition as a therapy for HCC has been evaluated in a series of clinical trials using combined AR-axis inhibition approaches routinely deployed in prostate cancer (PCa). This evidence concerns the gene AR and hepatocellular carcinoma.